ArticleMolecular biology reports2025
Genome mining identifies Micrococcus yunnanensis strain AZMABM 17 as a potential source of Antioxidant, Anti-Inflammatory, Antidiabetic, and Antiproliferative compounds.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe discovery and characterization of novel microbial strains are critical for advancing our understanding of microbial diversity and their potential applications in biotechnology and medicine.
methodsIn this study, we identified and characterized Micrococcus yunnanensis strain AZMABM 17 using 16 S rRNA sequencing and Average Nucleotide Identity (ANI) analysis. Whole-genome sequencing was performed to determine the genomic structure and functional potential of the strain. Functional annotation and predictive analysis of secondary metabolite biosynthesis gene clusters (BGCs) were also conducted. The bioactivity of the isolate was evaluated through antidiabetic, antioxidant, and anti-inflammatory assays by measuring inhibition using a spectrophotometer. Antiproliferative activity was assessed using MTT assays against the MCF-7 breast cancer cell line.
resultsThe 16 S rRNA sequencing revealed a 98.28% identity with Micrococcus sp. 3455 and Micrococcus sp. GS57, while ANI analysis showed a 98.30% similarity with Micrococcus yunnanensis DSM 21,948, confirming AZMABM 17 as a novel strain. Whole-genome sequencing revealed a circular chromosome of 2,435,094 base pairs with a GC content of 73%, encoding 2,183 protein-coding genes, including 949 assigned to Gene Ontology (GO) and 1,367 to KEGG Orthology (KO). Functional annotation identified genes involved in amino acid transport, carbohydrate metabolism, and secondary metabolite biosynthesis, including terpenoids and carotenoids. The strain exhibited significant antioxidant, antidiabetic, anti-inflammatory, and antiproliferative activities, with higher metabolite concentrations correlating with increased bioactivities. Predictive analysis identified six putative secondary metabolite biosynthesis gene clusters (BGCs), including terpene and NI-siderophore clusters, suggesting the potential to produce novel bioactive compounds.
conclusionsThese findings underscore the biotechnological potential of Micrococcus yunnanensis strain AZMABM 17, particularly in pharmaceutical and environmental applications.
Indexed as
Identifiers
41085814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.